Challenging issues: Sleep-wake, augmentation and quality of life

Sleep Medicine

Volumn 8, Issue SUPPL. 2, 2007, Pages

  Partinen, Markku ^a,b  

^a Rinnekoti Foundation Finland   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Depression; Dopamine agonists; Dopaminergic; Quality of life; Restless legs syndrome (RLS)

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; CIMETIDINE; DILTIAZEM; DOPAMINE RECEPTOR STIMULATING AGENT; FERRITIN; GABAPENTIN; HALOPERIDOL; LEVODOPA; LEVOMEPROMAZINE; LITHIUM SALT; METOCLOPRAMIDE; MIANSERIN; MIRTAZAPINE; NEUROLEPTIC AGENT; NIFEDIPINE; OLANZAPINE; OPIATE; PERPHENAZINE; PHENYTOIN; PLACEBO; PRAMIPEXOLE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; ROPINIROLE; UNINDEXED DRUG; VERAPAMIL;

ANAMNESIS; ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIAGNOSTIC PROCEDURE; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FERRITIN BLOOD LEVEL; HUMAN; LABORATORY TEST; LOW DRUG DOSE; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; SLEEP DISORDER; SLEEP WAKING CYCLE;

ANTICONVULSANTS; DEPRESSION; DIAGNOSIS, DIFFERENTIAL; DOPAMINE AGONISTS; HUMANS; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34447284981     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2007.04.007     Document Type: Article

References (74)

1. Hening W., Walters A.S., Allen R.P., et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 5 (2004) 237-246
2. Meissner H.H., Riemer A., Santiago S.M., et al. Failure of physician documentation of sleep complaints in hospitalized patients. West J Med 169 (1998) 146-149
3. Walters A.S. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord 10 (1995) 634-642
4. Walters A.S., LeBrocq C., Dhar A., et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 4 (2003) 121-132
5. AASM. The International classification of sleep disorders. 2nd ed. Rochester, Minnesota: American Academy of Sleep Medicine (AASM); 2005.
6. Walters A.S., Hickey K., Maltzman J., et al. A questionnaire study of 138 patients with restless legs syndrome: the 'Night-Walkers' survey. Neurology 46 (1996) 92-95
7. Ohayon M.M. Prevalence and correlates of nonrestorative sleep complaints. Arch Intern Med 165 (2005) 35-41
8. Spiegel K., Leproult R., and Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet 354 (1999) 1435-1439
9. Hublin C., Kaprio J., Partinen M., and Koskenvuo M. Insufficient sleep - a population-based study in adults. Sleep 24 (2001) 392-400
10. Meier-Ewert H.K., Ridker P.M., Rifai N., et al. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol 43 (2004) 678-683
11. Spiegel K., Leproult R., L'Hermite-Baleriaux M., et al. Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin. J Clin Endocrinol Metab 89 (2004) 5762-5771
12. Vorona R.D., Winn M.P., Babineau T.W., et al. Overweight and obese patients in a primary care population report less sleep than patients with a normal body mass index. Arch Intern Med 165 (2005) 25-30
13. Tiihonen M., Partinen M., and Närvänen S. The severity of obstructive sleep apnoea is associated with insulin resistance. J Sleep Res 2 (1993) 56-61
14. Grunstein R.R. Metabolic aspects of sleep apnea. Sleep 19 (1996) S218-S220
15. Coughlin S.R., Mawdsley L., Mugarza J.A., Calverley P.M., and Wilding J.P. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 25 (2004) 735-741
16. Svatikova A., Wolk R., Gami Apoor S., Pohanka M., and Somers Virend K. Interactions between obstructive sleep apnea and the metabolic syndrome. Curr Diab Rep 5 (2005) 53-58
17. McEwen B.S. Protective and damaging effects of stress mediators. N Engl J Med 338 (1998) 171-179
18. Grimpen F., Kanne P., Schulz E., et al. Endothelin-1 plasma levels are not elevated in patients with obstructive sleep apnoea. Eur Respir J 15 (2000) 320-325
19. Vgontzas A.N., Bixler E.O., Papanicolaou D.A., and Chrousos G.P. Chronic systemic inflammation in overweight and obese adults. JAMA 283 (2000) 2235 discussion 6
20. Parish J.M., and Somers V.K. Obstructive sleep apnea and cardiovascular disease. Mayo Clin Proc 79 (2004) 1036-1046
21. Abetz L., Allen R., Follet A., et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 26 (2004) 925-935
22. Testa M., and Simonson D. Assessment of quality-of-life outcomes. N Engl J Med 334 (1996) 835-840
23. Trenkwalder C., Stiasny K., Pollmacher T., et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind crossover trial. Sleep 18 (1995) 681-688
24. Atkinson M.J., Allen R.P., DuChane J., et al. Validation of the Restless Legs Syndrome Quality of Life Instrument (RLS-QLI): findings of a consortium of national experts and the RLS Foundation. Qual Life Res 13 (2004) 679-693
25. Abetz L., Allen R., Follet A., et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 26 (2004) 925-935
26. Allen R.P., Walters A.S., Montplaisir J., et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 165 (2005) 1286-1292
27. Abetz L., Vallow S.M., Kirsch J., et al. Validation of the Restless Legs Syndrome Quality of Life questionnaire. Value Health 8 (2005) 157-167
28. Bergner M., Bobbitt R., Carter W., and Gilson B. The sickness impact profile: development and final revision of a health status measure. Med Care 19 (1981) 787-805
29. Hunt S., McKenna S., McEwen J., Williams J., and Papp E. The Nottingham Health Profile: subjective status and medical consultations. Soc Sci Med 15A (1981) 221-229
30. Sevim S., Dogu O., Kaleagasi H., et al. Correlation of anxiety and depression symptoms in patients with restless legs syndrome: a population based survey. J Neurol Neurosurg Psychiatry 75 (2004) 226-230
31. Winkelmann J., Prager M., Lieb R., et al. "Anxietas tibiarum". Depression and anxiety disorders in patients with restless legs syndrome. J Neurol 252 (2005) 67-71
32. Brown L.K., Dedrick D.L., Doggett J.W., and Guido P.S. Antidepressant medication use and restless legs syndrome in patients presenting with insomnia. Sleep Med 6 (2005) 443-450
33. Picchietti D., and Winkelman J.W. Restless legs syndrome, periodic limb movements in sleep, and depression. Sleep 28 (2005) 891-898
34. Horvath J., Fross R.D., Kleiner-Fisman G., et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 19 (2004) 656-662
35. Hirani N., Bayliff C.C., and McCormack D.G. Diagnosis and management of pergolide-induced fibrosis. Mov Disord 20 (2005) 512-513
36. Dhawan V., Medcalf P., Stegie F., et al. Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline. J Neural Transm 112 (2005) 661-668
37. Montplaisir J., Nicolas A., Denesle R., and Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 52 (1999) 938-943
38. Montplaisir J., Denesle R., and Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol 7 (2000) 27-31
39. Partinen M., Hirvonen K., Alakuijala A., et al. Pramipexole in restless legs syndrome. A randomized double blind study. Sleep Med (2006)
40. Oertel W, Stiasny-Kolster K. Effective treatment of restless legs syndrome (RLS) with pramipexole: results of a 6-week, multi-centre, double blind, and placebo controlled study. Athens, Greece, 2005. Abstract # P2.
41. Winkelman J., Sethi K., Kushida C., Becker P., and Mahowald M. Pramipexole is efficacious and safe in treating RLS patients: results of a 12 weeks placebo controlled, fixed dose study WASM 2005, Berlin, Germany. Sleep Med 6 (2005) Abstract # 058
42. Trenkwalder C, Stiasny-Kolster K, and GR-PSG. Sustained efficacy of Pramipexole in Restless Legs Syndrome. Sleep Med 2005;6:S73.
43. Trenkwalder C., Stiasny-Kolster K., Kupsch A., et al. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord (2006)
44. Montplaisir J. Long-term treatment with pramipexole in restless legs syndrome. Eur J Neurol 13 (2006) 1306-1311
45. Partinen M., Hirvonen K., Jama L., et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study - the PRELUDE study. Sleep Med 7 (2006) 407-417
46. Miranda M., Kagi M., Fabres L., et al. Pramipexole for the treatment of uremic restless legs in patients undergoing hemodyalisis. Neurology 62 (2004) 831-832
47. Montplaisir J., Karrasch J., Haan J., and Volc D. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord 21 (2006) 1627-1635
48. Bogan R.K., Fry J.M., Schmidt M.H., Carson S.W., and Ritchie S.Y. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 81 (2006) 17-27
49. Giorgi L., Ritchie S.Y., and Kirsch J.M. Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score > or = 24 points - data from the ropinirole clinical trial programme. Curr Med Res Opin 22 (2006) 1867-1877
50. Walters A.S., Ondo W., Sethi K., Dreykluft T., and Grunstein R. Ropinirole versus placebo in the treatment of restless legs syndrome (RLS): a 12-week multicenter double-blind placebo-controlled study conducted in 6 countries. Sleep 26 (2005) A344
51. Trenkwalder C., Garcia-Borreguero D., Montagna P., et al. Ropinirole in the treatment of restless legs syndrome: results from a 12-week, randomised, placebo-controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 75 (2004) 92-97
52. Walters A.S., Ondo W.G., Dreykluft T., et al. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 19 (2004) 1414-1423
53. Pellecchia M.T., Vitale C., Sabatini M., et al. Ropinirole as a treamtent of restless legs syndrome in patients on chronic hemodyalisis. Clin Neuropharmacol 27 (2004) 178-181
54. Bliwise D.L., Freeman A., Ingram C.D., et al. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. Sleep Med 6 (2005) 141-147
55. Adler C.H., Hauser R.A., Sethi K., et al. Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology 62 (2004) 1405-1407
56. Möller J.C., Körner Y., Cassel W., et al. Sudden onset of sleep and dopaminergic therapy in patients with restless legs syndrome. Sleep Med 7 (2006) 333-339
57. Nordlander S.B. Intravenous iron in treatment of restless legs (TARKISTA). Acta Med Scand 145 (1953) 453-457
58. Schapira A.H.V. Restless legs syndrome: an update on treatment options. Drugs 64 (2004) 149-158
59. Thorpy M.J. New paradigms in the treatment of restless legs syndrome. Neurology 64 (2005) S28-S33
60. Estivill E., and de la Fuente V. The efficacy of ropinirole in the treatment of chronic insomnia secondary to restless legs syndrome: polysomnography data. Rev Neurol 29 (1999) 805-807
61. Trenkwalder C., Garcia-Borreguero D., Montagna P., et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 75 (2004) 92-97
62. Walters A.S., Ondo W.G., Dreykluft T., et al. Ropinirole is effective in the treatment of restless legs syndrome . TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 19 (2004) 1414-1423
63. Allen R.P., and Earley C.J. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 19 (1996) 205-213
64. Allen R.P., Picchietti D., Hening W.A., et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 4 (2003) 101-119 2003/3
65. Garcia-Borreguero D. Augmentation: understanding a key feature of RLS. Sleep Med 5 (2004) 5-6
66. Ondo W., Romanyshyn J., Vuong K.D., and Lai D. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 61 (2004) 1393-1397
67. Wunderlich G.R., Evans K.R., Sills T., et al. An item response analysis of the international restless legs syndrome study group rating scale for restless legs syndrome. Sleep Med 6 (2005) 131-139
68. Silber M.H., Girish M., and Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep 26 (2003) 819-821
69. Winkelman J.W., and Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 5 (2004) 9-14
70. Allen R.P., Picchietti D., Hening W.A., et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 4 (2003) 101-119
71. Dunger D.B., Leonard J.V., Wolff O.H., and Preece M.A. Effect of naloxone in a previously undescribed hypothalamic syndrome. A disorder of the endogenous opioid peptide system?. Lancet 1 (1980) 1277-1281
72. Walters A.S., Winkelmann J., Trenkwalder C., et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Movement Disorders: official journal of the Movement Disorder Society 16 (2001) 1105-1109
73. Silber M.H., Ehrenberg B.L., Allen R.P., et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 79 (2004) 916-922
74. Ondo W.G. Methadone for refractory restless legs syndrome. Mov Disord 20 (2005) 345-348